Trial reportTrials2013
Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial.
Trial report in Trials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01716481 (Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 Study
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Stem cell transplantation for ischemic stroke.The Cochrane database of systematic reviews · 2019Pooled it
- Pooled it
- Selective MicroRNA Packaging Reveals Distinct Core Signatures in Human Mesenchymal-Stromal-Cell-Derived Extracellular Vesicles.International journal of molecular sciences · 2025Article
- Stem cell therapy as a promising approach for ischemic stroke treatment.Current research in pharmacology and drug discovery · 2024Review
- Novel Therapeutic Opportunities for Neurodegenerative Diseases with Mesenchymal Stem Cells: The Focus on Modulating the Blood-Brain Barrier.International journal of molecular sciences · 2023Review
- Toxicity, Safety, and Efficacy Studies on Mesenchymal Stem Cells Derived fromCurrent issues in molecular biology · 2022Article
- Peripheral blood monocytes as a therapeutic target for marrow stromal cells in stroke patients.Frontiers in neurology · 2022Article
- The role of mesenchymal stem cell transplantation for ischemic stroke and recent research developments.Frontiers in neurology · 2022Review
- Mesenchymal stem cell therapy for ischemic stroke: A look into treatment mechanism and therapeutic potential.Journal of neurology · 2021Review
- Potential Mechanisms and Perspectives in Ischemic Stroke Treatment Using Stem Cell Therapies.Frontiers in cell and developmental biology · 2021Review
- Brain morphological and connectivity changes on MRI after stem cell therapy in a rat stroke model.PloS one · 2021Article
- Extracellular Vesicles Released from Neprilysin Gene-Modified Human Umbilical Cord-Derived Mesenchymal Stem Cell Enhance Therapeutic Effects in an Alzheimer's Disease Animal Model.Stem cells international · 2021Article
- A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived MonocytesFrontiers in pharmacology · 2021Article
- Mechanism of White Matter Injury and Promising Therapeutic Strategies of MSCs After Intracerebral Hemorrhage.Frontiers in aging neuroscience · 2021Review
- Cell-Based Therapies for Stroke: Are We There Yet?Frontiers in neurology · 2019Review
- Adult Stem Cells and Induced Pluripotent Stem Cells for Stroke Treatment.Frontiers in neurology · 2019Review
- Mesenchymal Stem Cell-Derived Extracellular Vesicle Therapy for Stroke: Challenges and Progress.Frontiers in neurology · 2019Review
- Fibroblasts as a practical alternative to mesenchymal stem cells.Journal of translational medicine · 2018Review
- Underregistration and Underreporting of Stem Cell Clinical Trials in Neurological Disorders.Journal of clinical neurology (Seoul, Korea) · 2018Article
- Serum-mediated Activation of Bone Marrow-derived Mesenchymal Stem Cells in Ischemic Stroke Patients: A Novel Preconditioning Method.Cell transplantation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecovery after a major stroke is usually limited, but cell therapy for patients with fixed neurologic deficits is emerging. Several recent clinical trials have investigated mesenchymal stem cell (MSC) therapy for patients with ischemic stroke. We previously reported the results of a controlled trial on the application of autologous MSCs in patients with ischemic stroke with a long-term follow-up of up to 5 years (the 'STem cell Application Researches and Trials In NeuroloGy' (STARTING) study). The results from this pilot trial are challenging, but also raise important issues. In addition, there have been recent efforts to improve the safety and efficacy of MSC therapy for stroke. METHODS AND
designThe clinical and preclinical background and the STARTING-2 study protocol are provided. The trial is a prospective, randomized, open-label, blinded-endpoint (PROBE) clinical trial. Both acute and chronic stroke patients will be selected based on clinical and radiological features and followed for 3 months after MSC treatment. The subjects will be randomized into one of two groups: (A) a MSC group (n = 40) or (B) a control group (n = 20). Autologous MSCs will be intravenously administered after ex vivo culture expansion with autologous ischemic serum obtained as early as possible, to enhance the therapeutic efficacy (ischemic preconditioning). Objective outcome measurements will be performed using multimodal MRI and detailed functional assessments by blinded observers. DISCUSSION: This trial is the first to evaluate the efficacy of MSCs in patients with ischemic stroke. The results may provide better evidence for the effectiveness of MSC therapy in patients with ischemic stroke.
trial registrationThis trial was registered with ClinicalTrials.gov, number NCT01716481.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.